Compare AENT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | ARMP |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | 697 | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.0M | 383.7M |
| IPO Year | N/A | 1996 |
| Metric | AENT | ARMP |
|---|---|---|
| Price | $7.20 | $8.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $15.00 |
| AVG Volume (30 Days) | 15.5K | ★ 67.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.37 | $1.17 |
| 52 Week High | $8.80 | $14.98 |
| Indicator | AENT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 40.87 |
| Support Level | $7.11 | $5.14 |
| Resistance Level | $7.41 | $12.11 |
| Average True Range (ATR) | 0.39 | 1.53 |
| MACD | -0.06 | -0.38 |
| Stochastic Oscillator | 15.79 | 8.67 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.